×

SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results

SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, today announced that it will provide an update on recent developments for Trevyent® and report second quarter 2015 financial results after the close of U.S. financial markets on August 13, 2015. Members of the SteadyMed management team will host a webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day to discuss these topics.

The live call may be accessed by dialing (866) 430-0928 for domestic callers and (704) 908-0411 for international callers. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.steadymed.com. A telephone replay of the call will be available by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers and entering the conference code: 94750929.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. In June 2015, SteadyMed signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.

CONTACT: Marylyn Rigby Director of Marketing and Investor Relations 925-272-4999 mrigby@steadymed.com Robert H. Uhl Managing Director Westwicke Partners 858-356-5932 robert.uhl@westwicke.com

Source: SteadyMed Therapeutics